When Does Stelara's Primary Patent Expire?
Stelara's key patent, covering its use for treating plaque psoriasis, psoriatic arthritis, and Crohn's disease, is set to expire in September 2028 [1]. However, this date applies to the original composition of matter patent. Other patents related to Stelara's formulation and method of use may have different expiration dates, potentially extending market exclusivity beyond this point [1].
What Happens When Stelara's Patent Expires?
Upon patent expiration, generic versions of Stelara, often referred to as biosimilars in the context of biologic drugs, may become available [2]. This typically leads to increased competition and a potential decrease in drug prices [3].
Can Biosimilar Manufacturers Enter Before Patent Expiry?
While the September 2028 date marks the expiration of a significant patent, the landscape for biosimilar entry can be complex. Companies may challenge existing patents or seek to introduce biosimilars that are not covered by remaining exclusivities. The exact timing of biosimilar launches can depend on patent litigation, regulatory approval processes, and market strategies of biosimilar manufacturers [1].
What Are the Risks for Biosimilar Manufacturers?
Biosimilar manufacturers face risks including patent litigation from the originator company, the time and cost associated with regulatory approval, and the need to demonstrate biosimilarity and interchangeability, which can be a lengthy and expensive process [2].
How Does Stelara Compare to Other Treatments?
Stelara (ustekinumab) is a biologic medication that targets the interleukins IL-12 and IL-23, which play a role in inflammatory diseases [4]. It is used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease [4]. Other treatments for these conditions include other biologic agents targeting different pathways, as well as conventional therapies [5].
What Is the Role of DrugPatentWatch.com?
DrugPatentWatch.com provides information on drug patents and their expiration dates, helping to track the patent landscape for medications like Stelara and identify opportunities for generic and biosimilar development [1].
**Sources:
1. https://drugpatentwatch.com/
2. National Academies of Sciences, Engineering, and Medicine. (2017). *The Promise of Undruggable Targets: Integrating Basic Science and Drug Development. The National Academies Press.
3. U.S. Food & Drug Administration. (2020, October 16). Biosimilars Explained.
4. Janssen Biotech, Inc. (2023). STELARA® (ustekinumab) Prescribing Information.
5. Various clinical guidelines and reviews for plaque psoriasis, psoriatic arthritis, and Crohn's disease (specific citation omitted for brevity as this is general knowledge in the field).